LimmaTech Biologics AG

Antimicrobial resistance (AMR) is one of the leading causes of death worldwide, and the need for innovative solutions has never been greater. The number of antibacterial agents approved and in development is insufficient to tackle the increasing global threat posed by the emergence and spread of drug-resistant infections. First, antibiotic agents only provide a treatment when the individual has been infected and suffers the disease and, second, the misuse of antibiotics accelerates the resistance against such agents. For nearly two decades, the team at LimmaTech Biologics has focused on developing broadly accessible vaccines addressing high-priority AMR and sexually transmitted infection (STI) threats, an area of rapidly growing medical need worldwide that is confirmed by the World Health Organization's (WHO) 2024 Bacterial Priority Pathogens List and recent recommendations on antibacterial pipeline trends. At LimmaTech, we are committed to addressing this urgent crisis by developing vaccine candidates that target some of the world’s most dangerous pathogens such as Shigella (with our partner Valneva), Staphylococcus aureus, and Neisseria gonorrhoeae. These pathogens represent critical targets in the global effort to curb AMR and STIs. Our candidates are designed to not only protect individuals from getting these infections and the severe health issues of the related diseases but also to reduce the spread of resistant strains worldwide, thereby reducing the use of antibiotics and preserving these as a last resort for treatment. Ready to learn more about the fight against AMR and STIs? Follow us to discover how LimmaTech is at the forefront of the global strategy against AMR, including the growing challenge of drug-resistant STIs. #AMR #Vaccines #GlobalHealth #AntimicrobialResistance

We are excited to partner with Valneva to accelerate the development of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis. We will collaborate on conducting Phase 2 trials with S4V after which Valneva will assume all further development. With no licensed Shigella vaccine currently available and the disease being a leading cause of fatal diarrheal disease worldwide, this strategic partnership aims to fill a critical need for low- and middle-income countries and travelers. The development of Shigella vaccines has also been identified as a priority by the World Health Organization (WHO). LimmaTech will receive an upfront payment of €10 million and be eligible for additional payments based on regulatory, development, and sales milestones, along with low double-digit royalties on sales. Stay tuned as we continue to expand our pipeline of vaccine candidates targeting microbial-based infectious diseases and work towards our mission of combating the growing threat of antimicrobial resistance. #VaccineDevelopment #GlobalHealth #Shigella #biotech Find the full press release here: https://lnkd.in/gRMEKW3G

I am delighted and honoured to join the fantastic team, board, and investors at LimmaTech Biologics AG, as a board member and Chair. LimmaTech is at the forefront of combatting the global antimicrobial resistance epidemic with a robust clinical stage pipeline and a team with deep experience and tack record in vaccine development . I am thrilled to be part of a company whose mission is to tackle a huge and growing unmet medical need and to making a meaningful impact on people's lives and well being.

We are excited to welcome Staph Leavenworth Bakali as independent Chairman of our Board of Directors. With over 30 years of senior executive and board-level experience in the life science and healthcare industries, he brings a wealth of expertise that will greatly benefit LimmaTech’s mission to address the global threat of antimicrobial resistance. Welcome to the team, Staph! #vaccines #antimicrobialresistance #team #healthcare #biotech Find the full press release here: https://lnkd.in/dMTzh3ya

To mark #WorldImmunizationWeek, we celebrate 50 years of progress since the first vaccine against smallpox. Vaccines continue to save millions of lives annually and play a crucial role in the fight against infectious diseases. However, our journey is far from over.   While we've made significant strides, many diseases still lack effective vaccines. We also need to raise awareness about the challenges posed by antimicrobial resistance (AMR). Responsible for approximately 5 million deaths annually, AMR is a growing concern, particularly in children under the age of five.   At LimmaTech, we're committed to advancing the development of vaccine candidates to protect lives from microbial infectious diseases and to also combat the rising threat of AMR. This week we celebrate the immense success of vaccines while supporting the global efforts to develop new vaccines and enhance access to immunization, ensuring a healthier future for all.

During #STIAwarenessWeek, we want to raise the awareness that anyone can be affected by sexually transmitted diseases. Did you know that gonorrhea is the second most common sexually transmitted disease with approximately 700,000 infections each year in the U.S. alone? Although gonorrhea can be treated with antibiotics, over the past 80 years the bacterium that causes the disease, Neisseria gonorrhoeae, has become resistant to nearly all available antimicrobial treatments. Today, there is only one recommended treatment option while the number of treatment failures and local outbreaks has been growing in several countries.   Therefore, prevention is the best protection to maintain sexual and reproductive health. At LimmaTech, we are dedicated to creating prophylactic vaccines that can deliver transformative value worldwide by preventing microbial infections as well as combating the rising threat of AMR.   Learn more here: www.lmtbio.com   #TalkTestTreat #vaccines

We’re pleased to announce that we’ve been awarded $2.2 million from CARB-X to support our gonorrhea vaccine program. This grant will fuel our efforts to develop a much-needed vaccine against this increasingly prevalent and globally transmitted infectious disease that has become highly resistant to available antimicrobial drugs. The need for a new solution is significantly growing: Gonorrhea, caused by Neisseria gonorrhoeae, is rapidly accelerating worldwide, with approximately 82 million people infected globally in 2020, and has as such been recognized as a Priority Bacterial Pathogen by the WHO. Our hexavalent vaccine candidate is designed not only to protect individuals at risk but also to prevent the spread of gonorrhea infections and to curb the growing threat of antimicrobial resistance. The funding, provided as part of CARB-X’s mission to accelerate innovative solutions to combat the rising global threat of drug-resistant bacteria, will be instrumental in expediting our development efforts. #vaccines #antimicrobialresistance Find the full press release here: https://lnkd.in/eHyAgUqY

We just announced positive interim results from our Phase I/II clinical trial evaluating Shigella4V, a tetravalent bioconjugate vaccine. This vaccine is designed to protect against shigellosis, which is caused by the Shigella bacterium and is one of the leading causes of diarrheal death, particularly in low- and middle-income countries. With the emergence of multi-drug-resistant strains in recent years, there is a growing need for options that can both protect and address antimicrobial resistance. Our S4V vaccine candidate has shown a favorable safety and tolerability profile. It holds the potential to not only prevent this potentially life-threatening infection in children but also to offer protection to travelers and military personnel visiting Shigella-endemic countries. #Vaccines #AntimicrobialResistance   Find the full press release here: https://bit.ly/3UPbBFb

We just announced positive interim results from our Phase I/II clinical trial evaluating Shigella4V, a tetravalent bioconjugate vaccine. This vaccine is designed to protect against shigellosis, which is caused by the Shigella bacterium and is one of the leading causes of diarrheal death, particularly in low- and middle-income countries. With the emergence of multi-drug-resistant strains in recent years, there is a growing need for options that can both protect and address antimicrobial resistance. Our S4V vaccine candidate has shown a favorable safety and tolerability profile. It holds the potential to not only prevent this potentially life-threatening infection in children but also to offer protection to travelers and military personnel visiting Shigella-endemic countries. #Vaccines #AntimicrobialResistance   Find the full press release here: https://bit.ly/3UPbBFb

We are excited to add Tenmile to LimmaTech’s syndicate, bringing our total Series A raise to $40 million.   The secured funds will be instrumental in advancing our proprietary self-adjuvanting and multi-antigen vaccine technology platform and our clinical candidates for Staphylococcus aureus and Shigella. With the support of our new and current investors, we will continue our mission to provide effective solutions against dangerous infections that are increasingly resistant to antibiotics. #Vaccines #Antimicrobialresistance #SeriesAFinancing   Find the full press release here: https://bit.ly/48Tv0ZR